Collegium Pharmaceutical (COLL) EBIT Margin (2016 - 2026)

Collegium Pharmaceutical has reported EBIT Margin for 11 years, with the latest figure at 1.85% in Q2 2026.

• On a quarterly basis, EBIT Margin fell 1682.0% year-over-year to 1.85% in Q2 2026; TTM through Jun 2026 was 19.48%, a 113.0% increase from a year earlier, with the FY2025 full-year figure at 23.01%, down 389.0% from the prior year.
• EBIT Margin was 1.85% for Q2 2026 at Collegium Pharmaceutical, down from 15.97% in the prior quarter.
• The five-year high for EBIT Margin was 41.2% in Q4 2023, with the low at 11.96% in Q1 2022.
• Average EBIT Margin over 5 years is 19.8%, with a median of 19.81% recorded in 2024.
• The largest YoY upside for EBIT Margin was 13306 bps in 2022 against a maximum downside of 3612 bps in 2022.
• Over 5 years, EBIT Margin stood at 8.36% in 2022, then surged by 393 bps to 41.2% in 2023, then tumbled by 49 bps to 20.95% in 2024, then jumped by 41 bps to 29.57% in 2025, then sank by 94 bps to 1.85% in 2026.
• The last three EBIT Margin figures came in at 1.85% (Q2 2026), 15.97% (Q1 2026), and 29.57% (Q4 2025), per Business Quant data.